Clinical Trial

Descemet Endothelial Thickness Comparison Trial I

Study acronym: DETECT I
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Descemet Endothelial Thickness Comparison Trial (DETECT) I is a multi-center, outcome assessor-masked, placebo-controlled clinical trial randomizing 160 patients in a 2x2 factorial design. The purpose of this study is to determine differences in visual outcomes between two types of corneal transplant surgeries, ultrathin Descemet stripping automated endothelial keratoplasty (UT-DSAEK) and Descemet membrane endothelial keratoplasty (DMEK), and to determine the effect of rho-kinase inhibitors on endothelial cell loss.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2022-03-15; most recent amendment 2026-05-06.
Status change: Recruiting → Active, Not Recruiting 2025-12-16
Status change: Not Yet Recruiting → Recruiting 2022-08-23
Trial Details
NCT Number NCT05289661
Lead Sponsor Stanford University
Collaborators: Oregon Health and Science University, University of California, San Francisco, University of California, Davis, Case Western Reserve University, Dartmouth-Hitchcock Medical Center, University of Pennsylvania, University of Miami, Wills Eye Hospital
Conditions Fuchs
Enrollment 160 participants
Start Date 2022-07-15
Primary Completion 2026-11-30 (estimated)
Study Completion 2027-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-08